Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Corcept Therapeutics is supported by a strengthening multi-product franchise, with 1Q26 revenues of approximately $165M and full-year guidance raised to a midpoint of $1B after positive early Lifyorli launches and record Korlym patient starts in March and April. The company’s core Cushing’s business looks set to recover as the pharmacy transition ended in February 2026 and the new vendor clears prior-authorizations, removing a key volume bottleneck. Its long-term upside is reinforced by relacorilant’s positive CHMP opinion for platinum-resistant ovarian cancer, superior ROSELLA efficacy, and a promising FDA resubmission path for Cushing’s syndrome that could further broaden the growth base.

Bears say

Corcept Therapeutics is viewed negatively because its valuation and operating outlook still depend heavily on a narrow set of products and pipeline catalysts, leaving the company exposed if relacorilant or other programs disappoint. While the resubmission announcement improves visibility on a regulatory path and suggests a potential second approval by YE 2026, the business still faces meaningful execution risk, with the prior base case assuming a new pivotal trial and a delayed commercial launch in 2029. Even with lower projected R&D expense and a pulled-forward launch to 2027, the investment case remains sensitive to clinical and regulatory outcomes rather than durable, diversified fundamentals.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.